Compare DIN & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIN | AMRN |
|---|---|---|
| Founded | 1958 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.8M | 304.3M |
| IPO Year | 1994 | 1998 |
| Metric | DIN | AMRN |
|---|---|---|
| Price | $27.86 | $13.95 |
| Analyst Decision | Hold | Strong Sell |
| Analyst Count | 7 | 1 |
| Target Price | ★ $29.00 | $12.00 |
| AVG Volume (30 Days) | ★ 291.3K | 63.6K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $879,300,000.00 | $181,104,000.00 |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | $0.64 | $1.26 |
| P/E Ratio | $25.18 | ★ N/A |
| Revenue Growth | 8.25 | ★ 39.22 |
| 52 Week Low | $19.52 | $9.44 |
| 52 Week High | $39.68 | $20.90 |
| Indicator | DIN | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 49.84 | 40.59 |
| Support Level | $27.52 | $13.69 |
| Resistance Level | $28.90 | $16.91 |
| Average True Range (ATR) | 1.18 | 0.66 |
| MACD | 0.10 | -0.07 |
| Stochastic Oscillator | 60.22 | 33.07 |
Dine Brands Global Inc owns and franchises thousands of restaurants under the International House of Pancakes (IHOP), Applebee's Neighborhood Grill + Bar (Applebee's), and the Fuzzy's Taco Shop (Fuzzy's) names. The company conducts its business through three reportable segments: Franchise, Company-owned restaurants, and Rental. The majority of its revenue is generated from the Franchise segment, which consists of IHOP, Applebee's, and Fuzzy's franchise operations and generates revenue mainly from royalties and advertising fees from several IHOP, Applebee's, and Fuzzy's franchised restaurants, in addition to revenues from the sale of proprietary IHOP and Fuzzy's products to its franchisees. Geographically, the majority of the company's revenues is generated from its domestic market.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.